“Although we are currently only talking about early findings, the XeMRI scans of non-hospitalised patients who are breathless - and 70 per cent of our local patients with Long COVID do experience breathlessness – may have similar abnormalities in their lungs. We need a larger study to identify how common this is and how long it will take to get better.” Professor Gleeson explained.
“We have some way to go before fully comprehending the nature of the lung impairment that follows a COVID-19 infection. But these findings, which are the product of a clinical-academic collaboration between Oxford and Sheffield, are an important step on the path to understanding the biological basis of long COVID and that in turn will help us to develop more effective therapies.”
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
The Pulmonary, Lung and Respiratory Imagining Sheffield (POLARIS) research group led by Professor Jim Wild at the University of Sheffield pioneered the methods, development and clinical applications of hyperpolarised gas lung MRI in the UK, performing the first clinical research studies in the UK and the world’s first clinical diagnostic scanning with this technology.
The study - C-MORE-POST in Oxford and MURCO in Sheffield - forms part of the University of Oxford’s C-MORE (Capturing the MultiORgan Effects of COVID-19) study, which feeds into the major national follow-up study PHOSP-COVID, led by the University of Leicester, which is investigating the long-term effects of COVID-19 on hospitalised patients.Back to HCB News